



## Suanfarma Appoints Pere Mañé as New CEO to Drive Industrial Growth and Global Expansion

Madrid, April 22, 2025

- Pere Mañé brings over 30 years of experience in pharmaceutical operations and CDMO leadership at global companies such as Uquifa, Boehringer Ingelheim, and Esteve Química.
- His appointment reinforces Suanfarma's commitment to industrial excellence and positions the company for accelerated international growth.

Suanfarma, a global company specializing in the development, production, and commercialization of active pharmaceutical ingredients (APIs) and high-value **CDMO services** for the health industry, has announced the appointment of **Pere Mañé Godina** as its new **Chief Executive Officer (CEO)**. This marks the beginning of a new chapter for the company, focused on **industrial consolidation, sustainable innovation, and global expansion**.

With a career spanning more than 30 years, Pere has held technical and strategic executive positions at leading pharmaceutical companies such as **Uquifa, Boehringer Ingelheim, and Esteve Química (Esteve Group)**. His experience ranges from technical and operational roles to executive positions such as **General Manager** and **Group Chief Industrial Operations Officer**.

Most recently, Pere played a key role in the **industrial transformation of Esteve**, positioning its chemical division as a global benchmark. Under his leadership, the company was recognized as **CDMO of the Year – Small Molecules** at the **DCAT 2025 Leadership Awards**, one of the industry's most prestigious honors.

This appointment aligns with Suanfarma's long-term strategic vision. **Carlos Alonso**, interim CEO since October 2024, will ensure a smooth transition and will remain with the company as **Executive Chairman**:

*"We are confident that Pere's deep sector knowledge, strategic mindset, and leadership experience will be instrumental in strengthening Suanfarma's market position and continuing to deliver high-value solutions to our customers and partners."*

Pere's arrival brings decisive momentum to Suanfarma's growth journey. His focus on operational excellence, advanced CDMO capabilities, and strong strategic partnerships will guide the company through its next phase with the following objectives:

- Streamlining industrial operations and integrating new technologies
- Strengthening relationships with global clients and key suppliers

- Accelerating international expansion
- Fostering a culture of innovation and sustainability

In the words of **Pere Mañé Godina**, *“Suanfarma has all the elements to lead the future of the industry: a solid foundation, a strong industrial platform, and a high-value international network supported by an exceptional team. I’m excited to begin this new chapter and work together to keep delivering innovative, efficient, and sustainable solutions to our clients.”*

## About Suanfarma

Founded in 1993, Suanfarma is a B2B partner in the life sciences sector, committed to health and innovation through the sustainable development, manufacturing, and distribution of high-quality pharmaceutical ingredients.

Through its Suanfarma CDMO division, the company offers advanced capabilities in fermentation and chemical synthesis projects, acting as a One Stop Shop for the development, scale-up, manufacturing, and commercialization of both innovative and generic APIs. All facilities comply with the highest industry standards and regulations.

With a global network of 12 local offices and presence in more than 70 countries, Suanfarma serves over 400 international clients.

Since 2021, Suanfarma has been part of the Archimed ecosystem, a private equity firm specialized in the healthcare sector that supports the company’s growth and global strategy through its expertise and resources.

## Contact

Silvia Martín de Cáceres

**Head of Marketing & Communications**

[comunicacion@suanfarma.com](mailto:comunicacion@suanfarma.com)

T + 34 91 344 68 90

C / Einstein, 8

28108, Alcobendas - Madrid - Spain